Highlights

  • Based out of Alberta, this company is a clinical-stage (pre-revenue) biotechnology company in phase II trials. Its patented process uses autologous stem cell therapy, wherein stem cells are sourced from a patient’s own blood. Harvested stem cells are processed, multiplied, and reintroduced to the patient’s body to repair damaged and/or dysfunctional tissues/organs.
          • This report is currently available to premium subscribers – Free subscribers will gain access on Aug 31st, 2022
            Join as a FREE member and get our research report delivered straight to your inbox, with a seven-day delay

Visit Hemostemix Inc. page for more research, discussion boards and to like, and share.


Are you enjoying the highlights?

Discover the company's fair value estimate from our certified analysts, identify potential risks, and explore exciting upcoming catalysts in our detailed report.

Already a member? Sign In